--- title: "P/E Ratio Insights for Eli Lilly and Co" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275014319.md" description: "Eli Lilly and Co (NYSE:LLY) shares are currently trading at $1029.05, down 7.05% in the session and 5.17% over the past month, but up 17.16% year-over-year. The company's P/E ratio is lower than the Pharmaceuticals industry's average of 122.22, suggesting potential undervaluation. While a low P/E can indicate weak growth prospects, it may also reflect investor optimism about future performance. Investors should consider the P/E ratio alongside other financial metrics and qualitative factors for a comprehensive analysis of the company's financial health." datetime: "2026-02-05T18:00:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275014319.md) - [en](https://longbridge.com/en/news/275014319.md) - [zh-HK](https://longbridge.com/zh-HK/news/275014319.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275014319.md) | [繁體中文](https://longbridge.com/zh-HK/news/275014319.md) # P/E Ratio Insights for Eli Lilly and Co Looking into the current session, **Eli Lilly and Co Inc. (NYSE:LLY)** shares are trading at $1029.05, after a **7.05%** drop. Over the past month, the stock decreased by **5.17%**, but over the past year, it actually went up by **17.16%**. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. ![Past Year Chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770314423_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ### How Does Eli Lilly and Co P/E Compare to Other Companies? The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. Eli Lilly and Co has a lower P/E than the aggregate P/E of **122.22** of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. ![Guage](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770314423_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. ### 相关股票 - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/zh-CN/quote/LLYX.US.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/zh-CN/quote/ELIL.US.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md) ## 相关资讯与研究 - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-CN/news/281395595.md) - [](https://longbridge.com/zh-CN/news/281203519.md) - [Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln](https://longbridge.com/zh-CN/news/281174134.md) - [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-CN/news/281171668.md) - [Lilly Pushes Back on Making Drug Price Deals Permanent](https://longbridge.com/zh-CN/news/281533388.md)